2-amino-4-phosphonobutyric acid has been researched along with haloperidol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chen, X; Ding, HF; Lang, L; Liu, G; Sun, SY; Yan, C | 1 |
| Ansari, MS; Baldwin, RM; Bubser, M; Conn, PJ; Johnson, KA; Jones, CK; Marvanova, M; Niswender, CM; Tantawy, MN | 1 |
3 other study(ies) available for 2-amino-4-phosphonobutyric acid and haloperidol
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
Topics: CRISPR-Cas Systems; Gene Targeting; Genes; Genes, Reporter; Genetic Engineering; Humans; Internal Ribosome Entry Sites; Transcription, Genetic | 2015 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Forelimb; Glycine; Haloperidol; Injections, Intraventricular; Male; Neostriatum; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Metabotropic Glutamate; Reserpine; Time Factors | 2013 |